Lavoltidine

Lavoltidine

Clinical data
Routes of administration	Oral
ATC code	none
Legal status
Legal status	Development terminated
Identifiers
IUPAC name [1-methyl-5-[3-[3-(piperidin-1-ylmethyl)phenoxy]propylamino]-1,2,4-triazol-3-yl]methanol
CAS Number	76956-02-0
PubChem CID	55473
ChemSpider	50093
UNII	X16K5179V5
CompTox Dashboard (EPA)	DTXSID0020785
Chemical and physical data
Formula	C19H29N5O2
Molar mass	359.474 g·mol−1
3D model (JSmol)	Interactive image
SMILES OCc1nn(C)c(n1)NCCCOc2cccc(c2)CN3CCCCC3

Lavoltidine (INN, ^[1] USAN, BAN; previously known as loxtidine; development code AH-23,844) is a highly potent and selective H₂ receptor antagonist which was under development by Glaxo Wellcome (now GlaxoSmithKline) ^[2] as a treatment for gastroesophageal reflux disease but was discontinued due to the discovery that it produced gastric carcinoid tumors in rodents. ^{[3] [4]}

See also

• H₂ receptor antagonist
• Sufotidine (analogous sequence in which a sulfonyl group replaces the hydroxyl group)

References

1. "International Nonproprietary Names for Pharmaceutical Substances. Recommended International Nonproprietary Names (Rec. INN): List 30" (PDF). WHO Drug Information. 4 (3). World Health Organization: 7. 1990. Retrieved 12 January 2016.
2. "Drug Profile: Lavoltidine". AdisInsight. Springer International Publishing AG. Retrieved 12 January 2016.
3. Washington N (1991). Antacids and anti-reflux agents. Boca Raton: CRC Press. ISBN   0-8493-5444-7.
4. Dictionary of organic compounds. London: Chapman & Hall. 1996. ISBN   0-412-54090-8.